Compare JDZG & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JDZG | KALA |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2M | 6.0M |
| IPO Year | 2024 | 2017 |
| Metric | JDZG | KALA |
|---|---|---|
| Price | $1.11 | $0.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 11.0K | ★ 21.9M |
| Earning Date | 04-17-2026 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $2,567,741.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.63 | ★ N/A |
| Revenue Growth | ★ 20.36 | N/A |
| 52 Week Low | $1.12 | $0.55 |
| 52 Week High | $14.00 | $20.60 |
| Indicator | JDZG | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 28.84 | 34.80 |
| Support Level | $1.21 | $0.55 |
| Resistance Level | $1.28 | $0.67 |
| Average True Range (ATR) | 0.11 | 0.22 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 2.17 | 5.00 |
Jiade Ltd specializes in providing one-stop comprehensive education supporting services to adult education institutions, through a wide range of software platform and auxiliary solutions. Auxiliary solutions encompass exam administration services and teaching support services throughout the entire teaching cycle. Specifically, the company offers pre-enrollment guidance on school/major selection and application strategy development, training for entrance exams, and assistance in the application process. The company also provides offline tutoring, exam administration services, guidance on graduation thesis, and social practice assistance included in the one-stop comprehensive education supporting services in the People's Republic of China.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.